Summary of Ultragenyx Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $160 million for Q3 2025, reflecting a 15% increase year-over-year and an 18% increase for the first nine months of 2025 compared to the same period in 2024.

Product Contributions:

Crysvita: $112 million (largest contributor)

Dojolvi: $24 million

Evkeeza: $17 million

Mepsevii: $7 million

Operating Expenses: $331 million, including R&D expenses of $216 million and SG&A expenses of $87 million.

Net Loss: $180 million, or $1.81 per share.

Cash Position: $447 million as of September 30, 2025, bolstered by a recent $400 million financing through the sale of Crysvita royalties, with payments deferred until January 2028.

2Strategic Updates and Business Highlights

Product Portfolio: Four commercial products are driving consistent double-digit revenue growth. Two BLA submissions are in progress for treatments targeting ultra-rare diseases.

Clinical Development:

GTX-102 for Angelman syndrome is in pivotal studies with data expected in late 2026.

UX143 for osteogenesis imperfecta is on track for Phase III data readouts by year-end.

Commercial Expansion: Continued growth in global markets, particularly for Crysvita, with increasing patient numbers and prescriber engagement across regions.

3Forward Guidance and Outlook

2025 Revenue Guidance: Reaffirmed at $640 million to $670 million, indicating 14% to 20% growth over 2024.

Crysvita Revenue: Expected between $460 million and $480 million, representing 12% to 17% growth.

Path to Profitability: The company aims for GAAP profitability by 2027, supported by ongoing revenue growth and strategic investments.

4Bad News, Challenges, or Points of Concern

High Operating Expenses: Operating expenses remain elevated, with significant R&D investments that may impact profitability in the near term.

Market Competition: The potential for multiple approved treatments for Angelman syndrome could complicate market dynamics and patient choice.

Clinical Risks: The success of pivotal trials for GTX-102 and UX143 is critical; any setbacks could impact future revenue and market position.

5Notable Q&A Insights

Clinical Data Expectations: The company anticipates sharing data from the Orbit and Cosmic studies in December or January, highlighting the importance of both studies for regulatory approval.

Market Dynamics for OI: Discussions around the adoption of setrusumab suggest that younger patients with severe disease may be prioritized for treatment.

Regulatory Strategy: The company is confident in its BLA submissions for UX111 and DTX401, with a focus on addressing FDA feedback to ensure successful filings.

Patient-Centric Approach: Insights from KOLs indicate that treatment decisions will be driven more by overall patient outcomes rather than specific clinical trial endpoints. Overall, Ultragenyx is positioned for growth with a solid product pipeline and strategic financial maneuvers, but it faces challenges related to high operating costs and competitive pressures in the rare disease market.